Statera BioPharma (original) (raw)
Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma".
| Property | Value |
|---|---|
| dbo:abstract | Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma". Cleveland BioLabs Inc. had been founded in partnership with the Cleveland Clinic in 2003 and moved to the Buffalo Niagara Medical Campus in 2007. It had license agreements and collaborations with the Cleveland Clinic, Roswell Park Comprehensive Cancer Center, the Children's Cancer Institute Australia, and the Armed Forces Radiobiology Research Institute, and specialized in research and development of products with the potential to treat cancer and protect against death following acute radiation syndrome. In 2018, Cleveland BioLabs entered into a joint venture with Buffalo-based Everon Biosciences. The joint venture, Genome Protection Inc., will develop pharmaceuticals that have anti-aging applications, using Cleveland Biolabs' acute radiation exposure drug, Entolimod.Genome Protection Inc. subsequently received a $10.5 million (US) investment from Russian oligarch Roman Abramovich. (en) |
| dbo:formerName | Cleveland BioLabs (en) Cytocom (en) |
| dbo:foundingYear | 2003-01-01 (xsd:gYear) |
| dbo:type | dbr:Public_company |
| dbo:wikiPageExternalLink | http://www.cbiolabs.com http://www.incuron.com http://www.panacelalabs.com |
| dbo:wikiPageID | 24342211 (xsd:integer) |
| dbo:wikiPageLength | 9366 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1088537289 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:Roman_Abramovich dbr:Roswell_Park_Comprehensive_Cancer_Center dbr:Animal_efficacy_rule dbr:In_vitro dbr:P53 dbr:Public_company dbr:Quinacrine dbc:Biotechnology_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbr:Rusnano dbr:Russian_Federation dbr:Cleveland_Clinic dbr:Entolimod dbr:Mycoplasma dbr:TLR_5 dbr:Cleveland,_Ohio dbr:Buffalo_Niagara_Medical_Campus dbr:Acute_radiation_syndrome dbr:HSF1 dbr:Food_and_Drug_Administration dbr:Fort_Collins,_Colorado dbc:2003_establishments_in_Ohio dbr:Armed_Forces_Radiobiology_Research_Institute dbc:Biotechnology_companies_established_in_2003 dbr:TLR6 dbr:Immunotherapy dbr:FACT_(biology) dbr:TLR2 dbr:NF-kB |
| dbp:date | April 2020 (en) |
| dbp:formerName | Cleveland BioLabs (en) Cytocom (en) |
| dbp:foundation | Cleveland, Ohio, 2003 (en) |
| dbp:industry | Pharmaceuticals (en) |
| dbp:keyPeople | (en) Yakov Kogan, CEO (en) |
| dbp:locationCity | dbr:Fort_Collins,_Colorado |
| dbp:locationCountry | USA (en) |
| dbp:name | Statera BioPharma, Inc. (en) |
| dbp:products | Anti-radiation and oncological products (en) |
| dbp:reason | Does "a quinacrine" refer to a quinacrine derivative or to quinacrine itself? (en) |
| dbp:subsid | Incuron, LLC (en) Panacela Labs, Inc. (en) |
| dbp:tradedAs | NASDAQ:STAB (en) |
| dbp:type | dbr:Public_company |
| dbp:wikiPageUsesTemplate | dbt:As_of dbt:Clarify dbt:Infobox_company dbt:Reflist dbt:URL dbt:Pharmaceutical_companies_of_the_United_States |
| dcterms:subject | dbc:Biotechnology_companies_of_the_United_States dbc:Companies_listed_on_the_Nasdaq dbc:2003_establishments_in_Ohio dbc:Biotechnology_companies_established_in_2003 |
| rdf:type | owl:Thing dbo:Company schema:Organization dul:Agent dul:SocialPerson dbo:Agent wikidata:Q24229398 wikidata:Q43229 wikidata:Q4830453 dbo:Organisation |
| rdfs:comment | Statera BioPharma, Inc. is an American clinical-stage biopharmaceutical company with a focus on novel immunotherapies. In 2021, Cleveland BioLabs merged with Cytocom, Inc, a clinical-stage biopharmaceutical company developing novel immunotherapies targeting autoimmune, inflammatory, infectious diseases, and cancers. The new company renamed itself "Statera BioPharma". (en) |
| rdfs:label | Statera BioPharma (en) |
| owl:sameAs | wikidata:Statera BioPharma https://global.dbpedia.org/id/4hpE2 |
| prov:wasDerivedFrom | wikipedia-en:Statera_BioPharma?oldid=1088537289&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Statera_BioPharma |
| foaf:name | Statera BioPharma, Inc. (en) |
| is dbo:wikiPageRedirects of | dbr:Cleveland_BioLabs |
| is dbo:wikiPageWikiLink of | dbr:Cleveland_BioLabs |
| is foaf:primaryTopic of | wikipedia-en:Statera_BioPharma |